The landmark PACIFIC phase 3 trial demonstrated that the addition of a PD-L1 inhibitor following concurrent chemoradiotherapy (cCRT) brought about clinical effects in patients with locally advanced NSCLC (15). The gene discussed is CD274; the disease is non-small cell lung carcinoma.